. intolerance). Ibrutinib is The present gold standard therapy for sufferers with relapsed/refractory condition, dependant on the outcomes of several phase I-III trials, 115–119 but This is certainly also modifying for two main good reasons: (i) an increasing proportion of individuals now receive ibrutinib as frontline therapy; and (ii) a handful